(ENXTBR:ARGX) reported positive topline data from its Phase 3 ADAPT OCULUS trial of VYVGART in ocular myasthenia gravis. The study met its primary endpoint, with statistically significant improvement ...

Efgartigimod led to statistically significant improvement in key symptoms of ocular myasthenia gravis compared with placebo in a phase 3 trial.

Efgartigimod alfa–hyaluronidase significantly improves ocular symptoms in adults with ocular myasthenia gravis, according to phase 3 trial data.

The Adapt Oculus trial is unique in that it includes a patient population often overlooked in clinical trials, patients ...

Positive results from Phase 3 ADAPT OCULUS study show VYVGART’s potential as the first targeted treatment for patients living with ocular MG Additional data from ADAPT SERON – the largest study of ...

Argenx SE (NASDAQ:ARGX) is one of the best NASDAQ stocks to buy according to hedge funds. On February 26, Argenx reported earnings for 2025, achieving its first year of annual operating profitability ...

Already on a roll with its first-in-class FcRn blocker Vyvgart, argenx has reported successful trial results that could pave the way for the fast-rising blockbuster to reach a new indication—ocular ...

Describe the most common clinical features that should alert the ophthalmologist to the diagnostic consideration of myasthenia gravis. Explain the pathophysiology connecting the human thymus to the ...

X recently announced results from additional analyses of its blockbuster FcRn inhibitor Vyvgart in the phase III Adapt Oculus study. The study evaluated the efficacy and safety of Vyvgart administered ...